We propose that EZH2 inhibitor could serve as therapeutic strategies for conditions like restenosis after angioplasty, atherosclerosis, and vein graft intimal thickening by inhibiting post-surgical VSMC proliferation and migration, thereby reducing restenosis incidence. This evidence concerns the gene EZH2 and atherosclerosis.